ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
2,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
2,2,Conjunctival haemorrhage,Conjunctival and corneal bleeding and vascular disorders,Ocular haemorrhages and vascular disorders NEC,Eye,N
2,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2,4,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
2,5,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,6,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
3,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
3,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
3,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
3,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,2,Haemorrhagic disorder,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
5,3,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
6,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
7,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
8,1,Phagocytosis,Cell metabolism disorders NEC,Metabolism disorders NEC,Metab,N
9,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
11,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
12,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
13,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,3,Menstrual disorder,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
14,1,Hip arthroplasty,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
14,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
14,3,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
14,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
15,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
16,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
17,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Alveolitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
19,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
19,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
19,3,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
20,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
20,2,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
21,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
22,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
26,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
27,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
28,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
29,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
30,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
31,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
32,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
35,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
35,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
36,1,Biopsy bone marrow abnormal,Bone marrow and immune tissue histopathology procedures,Haematology investigations (incl blood groups),Inv,N
36,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
36,3,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
36,4,Megakaryocytes increased,Bone marrow and immune tissue histopathology procedures,Haematology investigations (incl blood groups),Inv,N
36,5,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
36,6,Reticulin increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
37,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
38,1,Lymphoid tissue hyperplasia,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
38,2,Marrow hyperplasia,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
38,3,Reticulin increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
39,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
39,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
40,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
40,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
41,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
41,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
41,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
41,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
41,5,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
41,6,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
41,7,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
41,8,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
41,9,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
42,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,2,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
43,1,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
43,2,Neuropathic arthropathy,Osteoarthropathies,Joint disorders,Musc,N
43,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
43,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
44,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
45,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
45,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
45,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
45,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
46,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
46,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
46,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
46,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
47,1,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
47,2,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
48,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
48,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
49,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
50,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
50,2,Dental care,Dental and gingival therapeutic procedures,Head and neck therapeutic procedures,Surg,N
50,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
50,4,Haemorrhagic disorder,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
50,5,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
50,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
50,7,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
51,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
51,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
52,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
53,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
53,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
53,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
54,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
56,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
56,2,Embolic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
57,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
57,2,Embolic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
58,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
58,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
59,1,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
59,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
60,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
61,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
61,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
61,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
61,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
62,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
63,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
64,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
64,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
64,3,Leukaemia cutis,Leukaemias NEC,Leukaemias,Neopl,N
64,4,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
65,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
66,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
67,1,Endometrial hyperplasia,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
67,2,Postmenopausal haemorrhage,Menopausal effects on the genitourinary tract,Menopause related conditions,Repro,N
68,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
68,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
69,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
69,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
70,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
71,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
72,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
72,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
73,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
74,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
74,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
74,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
75,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
75,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
76,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
76,2,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
76,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
76,4,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
76,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
76,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
76,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
76,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
76,9,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
76,10,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
77,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
78,1,Exposure via breast milk,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
78,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
79,1,Leukoerythroblastic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
80,1,Drug specific antibody present,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
80,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
80,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
81,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
81,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
82,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
82,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
82,3,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
83,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,Y
83,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
83,3,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
83,4,Ischaemic cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
83,5,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
83,6,Therapeutic response delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
84,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
85,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
85,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
85,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
85,4,Joint warmth,Joint related signs and symptoms,Joint disorders,Musc,N
85,5,Red blood cell sedimentation rate increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
86,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
86,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
86,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
86,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
87,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
87,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
88,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
89,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
89,2,Adenoma benign,Neoplasms benign site unspecified NEC,Miscellaneous and site unspecified neoplasms benign,Neopl,N
89,3,Adhesion,General signs and symptoms NEC,General system disorders NEC,Genrl,N
89,4,Autoimmune thyroiditis,Acute and chronic thyroiditis,Thyroid gland disorders,Endo,N
89,5,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
89,6,Granuloma,Inflammations,General system disorders NEC,Genrl,N
89,7,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
89,8,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
89,9,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
89,10,Inflammation,Inflammations,General system disorders NEC,Genrl,N
89,11,Megakaryocytes increased,Bone marrow and immune tissue histopathology procedures,Haematology investigations (incl blood groups),Inv,N
89,12,Myocardial fibrosis,Myocardial disorders NEC,Myocardial disorders,Card,N
89,13,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,N
89,14,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
89,15,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
89,16,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
89,17,Thyroid atrophy,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
90,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
91,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
91,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
92,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
92,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
93,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
93,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
93,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
93,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
94,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
94,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
95,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
96,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
96,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
97,1,Cerebral venous thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
98,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
98,2,Transverse sinus thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
99,1,Cerebrovascular disorder,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
100,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
100,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
101,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
101,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
101,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
102,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
103,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
103,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
104,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
104,2,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
104,3,Ocular rosacea,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
104,4,Skin laxity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
105,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
105,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
105,3,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
105,4,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
105,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
105,6,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
105,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
105,8,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
105,9,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
105,10,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
105,11,Protein-losing gastroenteropathy,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
106,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
106,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
107,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
107,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
108,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
109,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
110,1,Multiple fractures,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
110,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
111,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
111,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
112,2,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
112,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
112,4,Eosinophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
112,5,Monocyte count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
112,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
112,7,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
112,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
113,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
113,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
113,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
113,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
114,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
115,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
116,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
117,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
118,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
119,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
121,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
121,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
122,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
123,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
123,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
124,1,Autoimmune haemolytic anaemia,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
125,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
126,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
126,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
127,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
128,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
128,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
129,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
129,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
130,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
130,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
130,3,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
130,4,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
131,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
131,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
132,2,Madarosis,Alopecias,Skin appendage conditions,Skin,N
133,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
133,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
133,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
133,4,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
133,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
133,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
133,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
134,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
134,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
134,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
135,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
135,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
136,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
136,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
136,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
136,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
137,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
137,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
137,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
138,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
139,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
140,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
140,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
140,3,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
140,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
141,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
141,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
143,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
143,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
143,3,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
143,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
143,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
143,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
143,7,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
143,8,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
143,9,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
143,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
143,11,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
143,12,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
143,13,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
143,14,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
143,15,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
143,16,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
144,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
144,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
144,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
144,4,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
145,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
146,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
146,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
146,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
146,4,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
146,5,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
147,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
148,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
148,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
149,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
150,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
150,2,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
150,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
150,4,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
150,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
152,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
152,2,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
152,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
153,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
153,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
154,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
154,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
154,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
154,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
154,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
155,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
155,2,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
156,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
156,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
157,1,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
157,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
157,3,Pleuritic pain,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
157,4,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
158,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
158,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
158,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
159,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
160,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
161,1,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
161,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
162,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
162,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
162,3,Onychogryphosis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
162,4,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
163,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
163,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
163,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
163,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
164,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
164,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
164,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
164,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
164,5,Urinary tract infection bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
165,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
166,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
167,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
168,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
169,1,Bronchitis,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
169,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
170,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
171,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
172,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,Y
173,1,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
174,1,Arterial thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
175,1,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
175,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
176,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
176,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
177,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
177,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
177,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
177,4,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
177,5,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
177,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
177,7,Myalgia,Muscle pains,Muscle disorders,Musc,N
177,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
177,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
178,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
179,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
180,1,Pulmonary venous thrombosis,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
181,1,Arterial thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
181,2,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
181,3,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
181,4,Venous thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
182,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
183,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
183,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
183,3,Delirium,Deliria,Deliria (incl confusion),Psych,N
183,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
183,5,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
183,6,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
183,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
183,8,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
184,1,Axonal neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
184,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
184,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
184,4,Peripheral sensorimotor neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
185,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
186,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
187,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
188,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
188,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
189,1,Polyneuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
190,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
190,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
190,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
191,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
191,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
191,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
191,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
192,1,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
193,1,Antiphospholipid syndrome,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
194,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
194,2,Cholestasis of pregnancy,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
194,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
195,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
195,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
195,3,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
195,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
195,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
195,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
195,7,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
195,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
195,9,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
195,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
195,11,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
195,12,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
195,13,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
195,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
195,15,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
195,16,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
195,17,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
195,18,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
195,19,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
196,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
197,1,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,Y
198,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
199,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
199,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
199,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
199,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
199,5,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
199,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
199,7,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
199,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
200,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
200,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
200,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
201,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
201,2,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
202,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
203,1,Cutaneous T-cell lymphoma,Mycoses fungoides,Lymphomas non-Hodgkin's T-cell,Neopl,Y
204,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
205,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
206,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
206,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
206,3,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
206,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
206,5,Extramedullary haemopoiesis,Haematological disorders,Haematological disorders NEC,Blood,N
206,6,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
206,7,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
206,8,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
206,9,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
206,10,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
206,11,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
206,12,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
206,13,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
206,14,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,Y
207,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
207,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
207,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
207,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
208,1,Electrocardiogram ST-T segment abnormal,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
208,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
209,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
209,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
209,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
209,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
209,5,Headache,Headaches NEC,Headaches,Nerv,N
209,6,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
209,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
209,8,Listless,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
209,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
209,10,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
209,11,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
209,12,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
210,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
210,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
210,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
210,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
210,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
210,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
211,1,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
212,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
213,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
214,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
214,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
215,1,Brain hypoxia,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
215,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
215,3,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
215,4,Evans syndrome,Anaemias haemolytic immune,Haemolyses and related conditions,Blood,N
215,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
215,6,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
215,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
215,8,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
215,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
215,10,Substance-induced psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
216,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
216,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
216,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
217,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
218,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
218,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
219,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
219,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
220,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
220,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
220,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
220,4,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
221,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
221,2,Cholestasis of pregnancy,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
221,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
221,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
221,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
221,6,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
222,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
223,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
223,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
223,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
223,4,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
223,5,Cushingoid,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
223,6,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
223,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
223,8,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
224,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
224,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
224,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
224,4,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
225,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
226,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
226,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
227,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
228,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
228,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
229,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
229,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
230,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
230,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
231,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
231,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
232,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
234,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
235,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
236,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
237,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
237,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
237,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
238,1,Neutralising antibodies,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
238,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
238,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
239,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
239,2,Tumour thrombosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
240,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
241,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
241,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
242,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
242,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
242,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
243,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
243,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
243,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
243,4,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
243,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
243,6,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
243,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
243,8,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
244,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,3,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
244,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
244,5,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
244,6,Superficial vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
245,1,Atrioventricular block second degree,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
245,2,Extrasystoles,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
245,3,Macrocytosis,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
245,4,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
245,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
245,6,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
245,7,Red blood cell agglutination,Red blood cell abnormal findings NEC,Red blood cell disorders,Blood,N
245,8,Red blood cell sedimentation rate increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
245,9,Sinus bradycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
246,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
246,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
246,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
247,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
247,2,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
247,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
248,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
248,2,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
248,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
249,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
250,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
250,2,Blood alkaline phosphatase abnormal,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
250,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
250,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
250,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
251,1,Oligospermia,Spermatogenesis and semen disorders,Sexual function and fertility disorders,Repro,N
252,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
252,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
252,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
252,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
253,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
254,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
254,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
255,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
256,1,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
257,1,Induced labour,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
257,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
258,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
258,2,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
258,3,Oral contusion,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
258,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
259,1,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
260,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
261,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
262,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
262,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
263,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
264,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
264,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
265,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
266,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
267,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
267,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
267,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
268,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
268,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
268,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
269,1,Antiphospholipid syndrome,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
269,2,Cerebral artery occlusion,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
269,3,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
269,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
270,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
271,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
272,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
272,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
273,1,Fibromyalgia,Muscle pains,Muscle disorders,Musc,N
273,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
274,1,Fibrosis,Fibrosis NEC,Tissue disorders NEC,Genrl,N
275,1,Loss of therapeutic response,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
275,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
276,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
277,1,Cerebral microhaemorrhage,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
277,2,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
278,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
278,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
278,3,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
278,4,Atherosclerotic plaque rupture,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
278,5,Atrial enlargement,Myocardial disorders NEC,Myocardial disorders,Card,N
278,6,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
278,7,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
278,8,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
278,9,Ventricular hypokinesia,Myocardial disorders NEC,Myocardial disorders,Card,N
279,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
279,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
280,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
280,2,Gestational diabetes,Pregnancy complicated by maternal disorders,Maternal complications of pregnancy,Preg,N
280,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
280,4,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
280,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
280,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
280,7,Ophthalmoplegia,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
280,8,Postpartum haemorrhage,Postpartum complications NEC,Postpartum and puerperal disorders,Preg,N
280,9,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
280,10,Pulmonary haemorrhage,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
280,11,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
281,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
282,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
282,2,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
283,1,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
284,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
285,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
286,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
286,2,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
286,3,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
286,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
287,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
287,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
287,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
287,4,Thrombotic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
288,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
288,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
289,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
289,2,Mucosal haemorrhage,Mucosal findings abnormal,General system disorders NEC,Genrl,N
289,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
289,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
290,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
290,2,Extra-axial haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,N
290,3,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
290,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
290,5,Haemorrhoidal haemorrhage,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
290,6,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
290,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
290,8,Post procedural haematoma,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
291,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
292,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
293,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
293,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
293,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
293,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
294,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
295,1,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
